Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


12345678910111213...1516»
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Improving Outcomes in Peripartum Cardiomyopathy with Vericiguat: A Clinical Case. (Pubmed Central) -  Feb 3, 2025   
    While this case suggests that vericiguat could be an effective adjunctive treatment for PPCM, it remains unclear whether these improvements were directly attributable to vericiguat or could have occurred with continued standard therapy alone. Further studies are needed to define the role of vericiguat in this condition.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal, Real-world evidence, Real-world:  Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study. (Pubmed Central) -  Dec 10, 2024   
    Trial completion date: Apr 2030 --> Apr 2032 | Trial primary completion date: Apr 2030 --> Apr 2032 In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal, Real-world evidence, Real-world:  Eligibility for vericiguat in a real-world, contemporary heart failure population. (Pubmed Central) -  Dec 10, 2024   
    In a real-world study, 9% of patients met the eligibility criteria of the VICTORIA trial, but up to 13% complied with guideline recommendations and up to 19% met FDA or EMA criteria. In Italy, drug costs would be covered by up to 10% of patients.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Pharmacological management of heart failure: a patient-centered approach. (Pubmed Central) -  Nov 18, 2024   
    In this context, a patient-centered approach that considers comorbidities and specific clinical scenarios when dosing HF medication is essential. Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Unleashing hope: Vericiguat reshapes the landscape of heart failure management. (Pubmed Central) -  Nov 14, 2024   
    Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials. No abstract available
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. (Pubmed Central) -  Oct 30, 2024   
    VICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational guideline-directed medical therapy, in a compensated ambulatory HF population. VICTOR will add important information to the evidence of the effects of vericiguat across the spectrum of patients with HFrEF.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial. (Pubmed Central) -  Oct 22, 2024   
    A trend towards enhanced efficacy of vericiguat in populations simulated from PARADIGM-HF and DAPA-HF was observed. These findings support further exploration of vericiguat in lower-risk HF populations as is being investigated in the ongoing VICTOR (a study of vericiguat in participants with chronic heart failure with reduced ejection fraction) trial.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Indian Experience with Vericiguat: A Review Based upon Case Series. (Pubmed Central) -  Oct 11, 2024   
    Vericiguat, a soluble guanylate cyclase (sGC) stimulator, a new entrant, seems to present a promising therapeutic option for HF with signs of worsening, and early initiation of this therapy may be beneficial in certain patient profiles. This article explores the potential benefits of early vericiguat initiation in four patient profiles who presented with WHF.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal, Adverse events, Real-world evidence, Real-world:  Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS. (Pubmed Central) -  Oct 10, 2024   
    Furthermore, the most frequently reported preferred terms (PT) was hypotension (n?=?86, ROR 25.92, PRR 24.11, IC 4.59, EBGM 24.07), followed by dizziness (n?=?52, ROR 6.44, PRR 6.20, IC 2.63, EBGM 6.20), malaise (n?=?25, ROR 3.59, PRR 3.54, IC 1.82, EBGM 3.54), blood pressure decreased (n?=?23, ROR 20.00, PRR 19.64, IC 4.29, EBGM 19.61), and anemia (n?=?21, ROR 6.67, PRR 6.57, IC 2.72, EBGM 6.57). This study extended the adverse reactions documented in the FDA instruction and provided supplementary evidence regarding the clinical safety of vericiguat.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat, Diabetes, and Heart (Pubmed Central) -  Oct 9, 2024   
    This study extended the adverse reactions documented in the FDA instruction and provided supplementary evidence regarding the clinical safety of vericiguat. No abstract available
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat and Cardiovascular Outcomes (Pubmed Central) -  Oct 9, 2024   
    P3
    In this post hoc analysis of VICTORIA, vericiguat compared with placebo significantly reduced the risk of cardiovascular death or HFH in patients with worsening HF with reduced ejection fraction regardless of T2DM status. (A Study of Vericiguat in Participants With Heart
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  Study to Investigate Improvement in Physical Function in SF-36 with Vericiguat Compared with Placebo in Participants with Post-COVID-19 Syndrome (clinicaltrials.gov) -  Sep 25, 2024   
    P2,  N=104, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Sep 2024 Not yet recruiting --> Recruiting | Phase classification: P2a --> P2 | Trial completion date: Oct 2023 --> Apr 2025 | Trial primary completion date: Sep 2023 --> Apr 2025
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF. (Pubmed Central) -  Sep 17, 2024   
    P2
    We evaluated 368 proteins associated with cardiovascular disease and inflammation in prerandomization blood samples from 763 VITALITY-HFpEF (Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With HFpEF) participants who had a left ventricular ejection fraction ?45% and a heart failure decompensation event within 6 months...These proteins also provide insights into the diverse pathophysiology of HFpEF and which patients may improve functional status during follow-up. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03547583.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Examination of the Suitability of Vericiguat in Non-Heart Failure with Preserved Ejection Fraction Patients with Improved Ejection Fraction. (Pubmed Central) -  Sep 14, 2024   
    When comparing patients with and without improved EF, a significant difference was observed in the Hb (OR = 1.66, 95%CI = 1.12-2.83, p = 0.028), early introduction (OR = 12.5, 95%CI = 1.58-149, p = 0.025), and initiation of Vericiguat after the administration of the Fantastic Four (OR = 9.79, 95%CI = 1.71-100.2, p = 0.022). In this study, the early administration of Vericiguat, haemoglobin value, and initiation of Vericiguat after the introduction of the Fantastic Four were identified as independent factors for eligibility in non-dialysis, non-HFpEF patients who were able to continue GDMT treatment for more than 6 months after adding Vericiguat.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat Attenuates Doxorubicin-Induced Cardiotoxicity through the PRKG1/PINK1/STING Axis. (Pubmed Central) -  Sep 11, 2024   
    Further studies showed that vericiguat improved mitochondrial dysfunction and reduced mtDNA leakage into the cytoplasm by up-regulating PRKG1, which activated PINK1 and then inhibited the STING/IRF3 pathway to alleviate DIC. These findings demonstrate for the first time that vericiguat has therapeutic potential for the treatment of DIC.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Preclinical, Journal:  Guanylate cyclase promotes osseointegration by inhibiting oxidative stress and inflammation in aged rats with iron overload. (Pubmed Central) -  Sep 2, 2024   
    This study intended to investigate the effect of vericiguat (VIT) on titanium rod osseointegration in aged rats with iron overload, and also explore the role of VIT in osteoblast and osteoclast differentiation...Furthermore, iron overload significantly decreased oxidative stress levels; however, these detrimental effects can be mitigated by VIT treatment. Collectively, our data provide compelling evidence that VIT has the potential to reverse the deleterious consequences of iron overload on osseointegration and bone mass during ageing.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical, Review, Journal:  Vericiguat in heart failure with reduced ejection fraction: hope or solid reality? (Pubmed Central) -  Aug 7, 2024   
    Furthermore, vericiguat has proved to be a valid therapeutic ally especially in those patients with comorbidities such that they cannot receive the classic four-pillar therapy of HF (in particular renal failure). In this review, the authors report on randomized clinical trials, substudies, and meta-analysis about vericiguat in HFrEF, emphasizing the strengths that would suggest the possible role of vericiguat as the fifth pillar of the HFrEF treatment, acknowledging that there are still gaps in the evidence that need to be clarified.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium. (Pubmed Central) -  Aug 7, 2024   
    In this review, the authors report on randomized clinical trials, substudies, and meta-analysis about vericiguat in HFrEF, emphasizing the strengths that would suggest the possible role of vericiguat as the fifth pillar of the HFrEF treatment, acknowledging that there are still gaps in the evidence that need to be clarified. Vericiguat could be considered for high-risk patients who have recently experienced worsening heart failure events despite being on quadrable therapy, but they should not have N-terminal pro-B-type natriuretic peptide levels exceeding 8000